Abstract
Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (≥ 25%) improvement in SS14 score between baseline and 2 months sustained for ≥4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters.The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t -test). A sustained (≥ 4 weeks) improvement (≥25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson's chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13–27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6–7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0–7.9) (log-rank, P = 0.84) for BSC patients, and 1-year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aapro MS, Martin C and Hatty S (1998) Gemcitabine: a safety review. Anti-Cancer Drugs 9: 191–201
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleisham SB and deHaes JC (1993) The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Barsevik A, Langer C, Brunet D, Grindel C, Leighton J and Luckscheider C (1997) Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel [abstract]. Proc Am Soc Clin Oncol 16: 44a
Batel-Copel M, Kornblith AB and Batel PC (1997) Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer 33: 29–32
Bergman B, Aaronson NK, Ahmedzai S, Kaasa S and Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A: 635–642
Bernhard J and Gelber RD (eds) (1998) Workshop on missing data in quality of life research in cancer clinical trials: practical and methodological issues. Stat Med 17: 5–7
Billingham LJ, Cullen MH, Woods AD and Chetiyawardana RC (1997) Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer: 3. Results of a randomised trial evaluating palliation and quality of life [abstract]. Lung Cancer 18: 9
Brinkley D (1985) Quality of life in cancer trials. BMJ 291: 685–686
Cox JD, Stetz J and Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341–1346
Cullen MH (1993) The MIC regimen in non-small cell lung cancer. Lung Cancer 9: 81–89
Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66–72
Fernandez C and Rosell R (1989) Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 28: 29–33
Hardy JR, Noble T and Smith IE (1989) Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60: 764–766
Harper PG, James LE, Spiro SG and Rudd RM (1997) Five day oral etoposide treatment for advanced small cell lung cancer (SCLC): quality of life (QOL) assessments in a randomised comparison with intravenous chemotherapy [abstract]. Lung Cancer 18 (Suppl 1): 204
Hopwood P (1996) Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different?. Semin Oncol 23: 60–64
Hopwood P (1997) Evidence for the impact of quality of life. Lung Cancer 18: 66
Hopwood P, Stephens RJ and Machin D for the MRC Lung Cancer Working Party (1994) Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 3: 339–352
Hopwood P and Stephens RJ on behalf of the Medical Research Council (MRC) Lung Cancer Working Party (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 7: 633–636
Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, Gibson D and Parmar MK (1998) Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. Eur J Cancer 34: 49–57
MRC LCWP (1996 a) Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 73: 406–413
MRC LCWP (1996 b) Randomised trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 8: 167–75
Noble S and Goa KL (1997) Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447–472
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909
Pocock S and Simon R (1975) Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics 31: 103–115
Stephens RJ, Hopwood P, Girling DJ and Machin D (1997) Randomized trials with quality of life endpoints. Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?. Qual Life Res 6: 225–236
Stephens RJ, Hopwood P and Girling D (1999) Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 79: 538–544
Stewart LA, Pignon JP, Parmar MKB, Le Chevalier T and Souhami RL on behalf of the NSCLC Collaborators Group (1994) A meta-analysis using individual patient data from randomised clinical trials (RCTs) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (3) Survival in the supportive care setting [abstract]. Proc Am Soc Clin Oncol 13: 337
Thatcher N, Anderson H, Betticher DC and Ranson M (1995) Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anti-Cancer Drugs 6: 39–48
Thatcher N, Hopwood P and Anderson H (1997) Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 33: S8–S13
World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization 48, Geneva
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Anderson, H., Hopwood, P., Stephens, R. et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. Br J Cancer 83, 447–453 (2000). https://doi.org/10.1054/bjoc.2000.1307
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1307
Keywords
This article is cited by
-
Patients and family caregivers report high treatment expectations during palliative chemotherapy: a longitudinal prospective study
BMC Palliative Care (2021)
-
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
International Journal of Clinical Oncology (2019)
-
Symptomlinderung durch Tumortherapie?
Der Schmerz (2018)
-
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
Cancer Chemotherapy and Pharmacology (2018)
-
Formulation and preclinical evaluation of 99mTc–gemcitabine as a novel radiopharmaceutical for solid tumor imaging
Journal of Radioanalytical and Nuclear Chemistry (2014)